Recent blog posts
The HERTHENA-Lung01 Phase 2 Trial demonstrated significant, lasting effects of Patritumab Deruxtecan in non-small cell lung cancer patients
Latest Hotspot
4 min read
The HERTHENA-Lung01 Phase 2 Trial demonstrated significant, lasting effects of Patritumab Deruxtecan in non-small cell lung cancer patients
15 September 2023
The HERTHENA-Lung01 Phase 2 Trial showed that Patritumab Deruxtecan brought about meaningful and durable effects in Patients with non-small cell lung cancer.
Read →
Samsung Bioepis collaborates with Sandoz to market Ustekinumab Biosimilar Candidate
Latest Hotspot
4 min read
Samsung Bioepis collaborates with Sandoz to market Ustekinumab Biosimilar Candidate
14 September 2023
Samsung Bioepis Co., Ltd. disclosed it has struck a commercialization pact with Sandoz regarding SB17, a potential biosimilar to Stelarai(ustekinumab).
Read →
OKYO Pharma Concludes Patient Recruitment for Phase 2 Clinical Trial of OK-101 to Dry Eye Syndrome
Latest Hotspot
3 min read
OKYO Pharma Concludes Patient Recruitment for Phase 2 Clinical Trial of OK-101 to Dry Eye Syndrome
14 September 2023
OKYO Pharma Limited has successfully enrolled its patient quota for the Phase 2 clinical trial.
Read →
Carrick Therapeutics Declares the U.S. FDA Approval the IND for CT7439, a First-In-Class Inhibitor of CDK12/13
Latest Hotspot
3 min read
Carrick Therapeutics Declares the U.S. FDA Approval the IND for CT7439, a First-In-Class Inhibitor of CDK12/13
14 September 2023
Carrick Therapeutics made an announcement that their IND application for CT7439 has been given the green light by U.S FDA.
Read →
Opus Genetics reports the administration of their gene therapy OPGx-LCA5 to the first participant of their phase 1/2 clinical trial
Latest Hotspot
3 min read
Opus Genetics reports the administration of their gene therapy OPGx-LCA5 to the first participant of their phase 1/2 clinical trial
14 September 2023
Opus Genetics has administrated to the first patient in its first-in-human Phase 1/2 clinical trial for OPGx-LCA5.
Read →
Eloxx Pharmaceuticals Shares Program Report on Phase 2 Alport Trial involving ELX-02
Latest Hotspot
3 min read
Eloxx Pharmaceuticals Shares Program Report on Phase 2 Alport Trial involving ELX-02
14 September 2023
Eloxx Pharmaceuticals, Inc. provided new information on the development of ELX-02 in the context of handling Alport syndrome caused by nonsense mutations.
Read →
Janssen presents an application for Marketing Authorisation to the EMA, requesting endorsement for Erdafitinib's utilization in the management of patients
Latest Hotspot
4 min read
Janssen presents an application for Marketing Authorisation to the EMA, requesting endorsement for Erdafitinib's utilization in the management of patients
14 September 2023
Janssen Pharmaceuticals filed a Marketing Authorisation Application with EMA to get approval for Erdafitinib. The drug is for adult patients with advanced or metastatic urothelial carcinoma, showing progression after a PD-1/PD-L1 inhibitor therapy, with susceptible FGFR3 mutations.
Read →
2023 WCLC | AstraZeneca's EGFR-TKI Osimertinib Mesylate New Indication Phase 1b Clinical Data Selected for Oral Presentation
Latest Hotspot
3 min read
2023 WCLC | AstraZeneca's EGFR-TKI Osimertinib Mesylate New Indication Phase 1b Clinical Data Selected for Oral Presentation
14 September 2023
The FAVOUR study's interim analysis results on Alflutinib Mesylate for treating EGFR exon 20-insertion mutated NSCLC were orally presented at the 2023 WCLC. The drug is developed by Shanghai Allist Pharmaceuticals and ArriVent Biopharma.
Read →
Chia Tai Tianqing Pharmaceutical initiates global multicenter phase III clinical trials for the pan-PPAR agonist Lanifibranor
Latest Hotspot
4 min read
Chia Tai Tianqing Pharmaceutical initiates global multicenter phase III clinical trials for the pan-PPAR agonist Lanifibranor
13 September 2023
On Sept 11, 2023, Chia Tai Tianqing Pharmaceutical launched a global phase III trial, evaluating Lanifibranor's efficacy and safety in adult NASH patients with stage 2/3 hepatic fibrosis, excluding cirrhosis.
Read →
Abbisko Therapeutics' CSF-1R Inhibitor, Pimicotinib, Approved for Global Multicenter Phase 3 Clinical Trials in Europe
Latest Hotspot
3 min read
Abbisko Therapeutics' CSF-1R Inhibitor, Pimicotinib, Approved for Global Multicenter Phase 3 Clinical Trials in Europe
13 September 2023
On September 11, 2023, Abbisko Therapeutics announced that its innovative CSF-1R inhibitor pimicotinib (ABSK021) was approved by the European Medicines Agency.
Read →
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
Latest Hotspot
3 min read
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
13 September 2023
Biotech firm, Phanes Therapeutics, has announced its Phase 1 clinical trial of PT217, a first-in-class drug targeting DLL3 and CD47 in small cell lung cancer. The trial uses a new IgG-like bispecific antibody and the first patient has been treated.
Read →
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
Latest Hotspot
4 min read
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
13 September 2023
Biotech firm CymaBay Therapeutics, Inc. revealed positive Phase 3 trial outcomes for seladelpar, a novel treatment for liver and chronic diseases, including primary biliary cholangitis. Meeting all primary and key secondary endpoints.
Read →